Komori
Rohto Pharmaceutical (4527) · RiskRestated

Market risks from seasonal factors and intensifying competition

First written in FY2016. 13 of 25 entries say "Restated". Latest entry: FY2024-Q3.

25entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018-Q1 – FY2019-Q2MaterialisedFY2019-Q3 – FY2020RestatedFY2022-Q1 – FY2024-Q32016: 320162017: 420172018: 320182019: 320192020: 420202021: 320212022: 220222023: 220232024: 1
Same theme, other companies

Rohto Pharmaceutical moved to the "Worse" side of this theme in 2016, 3 years before the typical company in this theme (2019).

The whole theme swung hardest in 2025: 12 of 21 companies on the "Worse" side.

8 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 22 companies compared. The sentences above are computed from all 22.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  2. FY2024-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  3. FY2024-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  4. FY2023-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  5. FY2023-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  6. FY2022-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  7. FY2021MaterialisedAnnual report

    「In addition to the decline in sales of products such as sunscreen and lip balm due to restrictions on going out amid the spread of COVID-19 and the entrenchment of mask-wearing culture, inbound demand also remained weak.」

    Changes in seasonal and stay-at-home-related demand, mask-wearing culture and weak inbound demand were evident over the full year in declining sales of sunscreen, lip balm and other products.
  8. FY2021-Q3MaterialisedAnnual report

    「In addition to the impact of the resurgence of COVID-19 and the decline in sales of products such as lip balm due to the entrenchment of mask-wearing culture, inbound demand also remained weak.」

    The entrenchment of mask-wearing culture, the resurgence of infectious diseases and weak inbound demand are evident in actual sales performance through the decline in sales of products such as lip balm.
  9. FY2021-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  10. FY2021-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  11. FY2020MaterialisedAnnual report

    「Meanwhile, moisturizing products were sluggish as the trend toward warmer winters continued, and sales of Melano CC Medicated Intensive Blemish Care Essence also declined as inbound demand slowed.」

    Warm winters and slowing inbound demand were evident in full-year product sales through sluggish sales of moisturizing products.
  12. FY2020-Q3MaterialisedAnnual report

    「Although sales were affected by the Hong Kong protests and a boycott of Japanese products in South Korea, eye drops and sunscreen performed steadily.」

    The Hong Kong protests and the boycott of Japanese products in South Korea are explicitly identified as factors affecting the Asian business. Meanwhile, eye drops and sunscreen performed steadily.
  13. FY2020-Q2MaterialisedAnnual report

    「Although the US economy was on a moderate recovery trend, supported by steady personal consumption, sales struggled to grow due to intensifying competition in eye drops.」

    Sales of eye drops in the United States were sluggish due to intensifying competition, indicating that market competition risk has materialized in actual sales performance.
  14. FY2020-Q1MaterialisedAnnual report

    「Although the US economy was on a moderate recovery trend, supported by steady personal consumption, sales struggled to grow due to intensifying competition in eye drops.」

    Sales of eye drops in the United States were sluggish due to intensifying competition, indicating that market competition risk has materialized in actual sales performance.
  15. FY2019-Q3MaterialisedAnnual report

    「In Japan, high-value-added products performed well, but skincare-related moisturizing products were sluggish as the trend toward warmer winters continued. Inbound demand also recorded slower growth.」

    Seasonal-factor and demand-fluctuation risks are evident in actual sales performance through sluggish sales of moisturizing skincare products due to warm winters and slower growth in inbound demand.
  16. FY2019-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  17. FY2019-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  18. FY2018-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  19. FY2018-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  20. FY2018-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    The company states that there have been no material changes in market risks related to seasonal factors and intensifying competition.
  21. FY2017MaterialisedAnnual report

    「In skincare-related products, sales of the Hada Labo series declined amid intensifying competition, although the men's deodorant brand De Ou performed well.」

    The market competition risk continues to be evident in actual sales performance through the decline in sales of the Hada Labo series caused by intensifying competition.
  22. FY2017-Q3MaterialisedAnnual report

    「In addition to the impact of foreign-currency translation due to the stronger yen, sales of flagship lip balm products and OXY, where competition remains intense, were sluggish.」

    The market competition risk is evident in actual sales performance through sluggish sales of OXY, where competition remains intense.
  23. FY2017-Q2MaterialisedAnnual report

    「The impact included continued intensification of competition in Japan, unfavorable weather and lower pharmaceutical shipment prices following a review of rebate arrangements.」

    Intensifying competition and adverse weather are explicitly identified as factors behind the decline in sales in Japan, indicating that market and seasonal-factor risks have materialized.
  24. FY2017-Q1MaterialisedAnnual report

    「In addition to continued intensification of competition in sunscreen, the core Hada Labo series also struggled to grow.」

    The impact of intensifying competition is evident in sluggish sales of sunscreen and the flagship Hada Labo series.
  25. FY2016First statedAnnual report

    「Changes in shipments and returns due to seasonal factors such as cool summers, warm winters and pollen counts, as well as greater-than-expected declines in market prices amid a highly competitive environment, may affect operating performance and financial condition.」

    Shipment and return fluctuations caused by cool summers, warm winters and pollen levels, together with declining market prices amid competition, are identified as external-factor risks.
Moved together

"Risk of declines in the value of partners and investees" moved the same way as this thread, in the same document, in 11 of its 25 moves.

111010842★123456
  1. ★This thread
  2. 1Risk of declines in the value of partners and investees11×
  3. 2Political, Economic and Legal/Regulatory Risks Overseas10×
  4. 3Risk From Fluctuations in Foreign Exchange Rates, Share Prices and Interest Rates10×
  5. 4Collection Risk for Trade Receivables and Loans8×
  6. 5Growth in Overseas Revenue4×
  7. 6Demand, supply chain and financial market risks arising from COVID-192×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.